AbbVie Inc. (LON: 0QCV)

London flag London · Delayed Price · Currency is GBP · Price in USD
146.95
0.00 (0.00%)
Jul 21, 2022, 7:14 PM BST
-9.35%
Market Cap 253.76B
Revenue (ttm) 41.43B
Net Income (ttm) 3.79B
Shares Out n/a
EPS (ttm) 2.14
PE Ratio 66.94
Forward PE n/a
Dividend 4.84 (2.77%)
Ex-Dividend Date Jan 15, 2025
Volume 123,965
Open 147.24
Previous Close 146.95
Day's Range 146.95 - 154.06
52-Week Range 131.22 - 167.80
Beta 0.61
Analysts n/a
Price Target n/a
Earnings Date Jan 31, 2025

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]

Sector Healthcare
Founded 2012
Employees 50,000
Stock Exchange London Stock Exchange
Ticker Symbol 0QCV
Full Company Profile

Financial Performance

In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.

Financial numbers in USD Financial Statements

News

There is no news available yet.